Invasive Candidiases Clinical Trial
Official title:
Influence of Open and Laparoscopic Abdominal Surgery Involving the Intestinal Tract on Serum 1,3-ß-D-Glucan (BDG) Values
Candida species are both known to colonize physiologically mucosal surfaces in the human body
without causing signs or symptoms of infection and to cause a wide variety of diseases,
including mucocutaneous infections and potentially fatal invasive infections of the
bloodstream or organs. Throughout the past decades, invasive fungal infections (IFIs) are of
increasing importance even in non-neutropenic patients who are in need of treatment in
intensive care units (ICU) or have undergone major surgeries. Several factors like parenteral
nutrition, central venous catheters, broad spectrum antibiotics admission, disturbance of
gastrointestinal mucosa integrity have been associated with an increased incidence of IFIs.
Positive testing for 1,3-ß-D-Glucan (BDG) in serum is widely used to assess invasive fungal
infections. It detects circulating BDG, which is part of the fungal cell wall of clinical
relevant fungi such as Candida spp. and Aspergillus spp..
The issue of BDG kinetics after intestinal mucosal damage (e.g. mucositis or gut surgery) is
poorly understood. Intestinal mucosal damage is characterized by a loss of integrity of the
intestinal mucosal barrier and increasing translocations of bacterial and/or fungal
commensals of the gastrointestinal tract.
In abdominal surgery a key concern in serum BDG kinetics is the potential introduction of BDG
from surgical sponges and gauze or mucosal damage due to surgical damage of the mucosal
integrity. Compared to open abdominal surgery in laparoscopic abdominal surgery sponges and
gauze are rarely used. As life-threatening intraabdominal candidiasis occurs in 30 to 40% of
high-risk abdominal surgical intensive care unit (ICU) patients it is of utmost importance to
obtain reliable BDG values for diagnosis or exclusion of invasive candidiasis.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03667690 -
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
|
Phase 3 | |
| Completed |
NCT05848492 -
Efficacy of Prophylactic Fluconazole Therapy in Preterm and Very Low Birth Weight Neonates in Preventing Invasive Fungal Infection.
|
Phase 3 | |
| Recruiting |
NCT03090334 -
A B-D-Glucan Driven Antifungal Stewardship Approach for Invasive Candidiasis
|
N/A | |
| Recruiting |
NCT03450005 -
ECMM Candida Registry - CandiReg
|
||
| Completed |
NCT04148287 -
An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
|
Phase 2 | |
| Recruiting |
NCT03717623 -
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
|
Phase 4 |